Elacestrant

A randomized phase 3 trial designed to evaluate elacestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer met both of its primary endpoints, according to the agent’s manufacturer.

The FDA granted fast track designation to elacestrant for the treatment of ER-positive, HER-2-negative advanced or metastatic breast cancer, according to the drug’s manufacturer.

Healio spoke with Roberto A. Leon-Ferre, MD, about recent approvals in breast cancer.